{"drugs":["Luliconazole","Luzu"],"mono":{"0":{"id":"930829-s-0","title":"Generic Names","mono":"Luliconazole"},"1":{"id":"930829-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930829-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Tinea corporis:<\/b> apply TOPICALLY to affected skin and approximately 1 inch of the immediate surrounding area(s) once daily for 1 week<\/li><li><b>Tinea cruris:<\/b> apply TOPICALLY to affected skin and approximately 1 inch of the immediate surrounding area(s) once daily for 1 week<\/li><li><b>Tinea pedis:<\/b> apply TOPICALLY a thin layer to affected area(s) and approximately 1 inch of the immediate surrounding area(s) once daily for 2 weeks<\/li><\/ul>"},"1":{"id":"930829-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"930829-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Tinea corporis<\/li><li>Tinea cruris<\/li><li>Tinea pedis<\/li><\/ul>"}}},"3":{"id":"930829-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930829-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930829-s-3-10","title":"Precautions","mono":"report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch <br\/>"},{"id":"930829-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930829-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930829-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Application site reaction (less than 1%)<br\/>"},"6":{"id":"930829-s-6","title":"Drug Name Info","sub":{"0":{"id":"930829-s-6-17","title":"US Trade Names","mono":"Luzu<br\/>"},"2":{"id":"930829-s-6-19","title":"Class","mono":"<ul><li>Antifungal<\/li><li>Imidazole<\/li><\/ul>"},"3":{"id":"930829-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930829-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930829-s-7","title":"Mechanism Of Action","mono":"Luliconazole is an azole antifungal that appears to inhibit the conversion of lanosterol to ergosterol (a component of fungal cell membranes) by inhibiting the enzyme lanosterol demethylase. Inhibition of the conversion of lanosterol to ergosterol causes accumulation of lanosterol and a decreased amount of ergosterol in fungal cell wall.<br\/>"},"8":{"id":"930829-s-8","title":"Pharmacokinetics","sub":[{"id":"930829-s-8-23","title":"Absorption","mono":"Tmax, Topical: 16.9 hours after first dose, 5.8 hours after final dose (tinea pedis); 21 hours after first dose, 6.5 hours after final dose (tinea cruris) <br\/>"},{"id":"930829-s-8-24","title":"Distribution","mono":"Protein binding: greater than 99% <br\/>"}]},"9":{"id":"930829-s-9","title":"Administration","mono":"<b>Topical<\/b><br\/>topical use only; not for oral, ophthalmic, or intravaginal use <br\/>"},"10":{"id":"930829-s-10","title":"Monitoring","mono":"improvement in the signs or symptoms of interdigital tinea pedis, tinea cruris, or tinea corporis is indicative of efficacy<br\/>"},"11":{"id":"930829-s-11","title":"How Supplied","mono":"<b>Luzu<\/b><br\/>Topical Cream: 1 %<br\/>"},"13":{"id":"930829-s-13","title":"Clinical Teaching","mono":"<ul><li>Side effects may include application site reactions.<\/li><li>Advise patient that drug is not for oral, intravaginal, or ophthalmic use.<\/li><\/ul>"}}}